Cabaletta Bio (NASDAQ:CABA) is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.
The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3. In parallel, Cabaletta has advanced DESCA-1 into early clinical investigation for systemic sclerosis, targeting autoreactive B cells implicated in fibrotic and vascular manifestations. These programs underscore Cabaletta’s strategy of translating its CAAR-T approach into a pipeline of precision immunotherapies for high-unmet-need autoimmune conditions.
Headquartered in Philadelphia, Pennsylvania, Cabaletta Bio conducts clinical trials across the United States and Europe, collaborating with leading academic centers and biopharmaceutical partners. Since its founding in 2018, the company has built in-house capabilities for cell therapy research, process development and scalable manufacturing to support its expanding pipeline and ensure consistent production of CAAR-T products.
Guided by a management team with extensive expertise in immunology, cell therapy and clinical development, Cabaletta Bio is focused on advancing its platform toward regulatory milestones and broader clinical evaluation. Through its targeted approach, the company seeks to bring transformative treatments to patients suffering from debilitating autoimmune diseases.
